Yasunori Nakagawa
Tokyo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment.
Journal: Clinical lymphoma, myeloma & leukemia
Published: December 30, 2017
Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial.
Journal: The Lancet. Haematology
Published: August 17, 2015
Role of microRNA-29b in myelodysplastic syndromes during transformation to overt leukaemia.
Journal: Pathology
Published: May 20, 2015
Impacts of new agents for multiple myeloma on development of secondary myelodysplastic syndrome and acute myeloid leukemia.
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
Published: May 23, 2014
A phase 1/2 study of bosutinib in Japanese adults with Philadelphia chromosome-positive chronic myeloid leukemia.
Journal: International journal of hematology
Published: May 08, 2014
Increased level of KL-6 in a BJP-λ-type multiple myeloma patient with poor prognosis
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
Published: June 26, 2012
Intensive chemotherapy for elderly patients with acute myelogeneous leukemia: a propensity score analysis by the Japan Hematology and Oncology Clinical Study Group (J-HOCS).
Journal: Annals of hematology
Published: March 24, 2012
Showing 1-9 of 9
Last Updated: 09/26/2026